RNA Sequencing of Ishikawa Cell Line with NCF2 Knockdown Using Small Interfering RNA

Progestin therapy is one of the preferred treatment modalities for early-stage endometrial cancer patients wishing to retain fertility and for conservatively managing advanced endometrial cancer. However, a significant number of patients currently do not benefit from progestin therapy due to issues such as progestin resistance. In the past, we established a medroxyprogesterone acetate-resistant Ishikawa cell line. From this, we identified the NCF2 gene, which was highly expressed in the resistant group. Functional validation experiments revealed that knocking down NCF2 can effectively reverse progestin resistance. To explore its mechanism, we performed RNA sequencing post-NCF2 knockdown. Sequencing samples were divided into two groups, with three replicates each. The control group was transfected with negative control small interfering RNA (siRNA), while the experimental group was transfected with siRNA targeting the knockdown sequence. Samples were collected 72 hours post-transfection for RNA sequencing.